Trial Profile
A randomized, double-blinded study of simvastatin 20 mg/day versus Vytorin [ezetimibe/simvastatin] 10/20 in subjects with lipid profiles not meeting current NCEP [National Cholesterol Education Program] guidelines, following a low-carbohydrate diet
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms LOCUST
- Sponsors Merck Sharp & Dohme Corp.
- 05 May 2010 Results published in American Heart Journal.
- 10 Dec 2007 New trial record.